London Regional Cancer Program, London Health Sciences Centre

London, Ontario N6A 5W9

0 studies enrolling now · 8 studies all time

What they study most

Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Giant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component, Gliosarcoma, HER2-positive Breast Cancer, KRAS p.G12C Mutant Advanced Solid Tumors, Neoplasms, Pancreas Adenocarcinoma, Pancreatic Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) — Completed
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) — Completed
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) — Completed
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer — Completed
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer — Completed